NVCR News and Press, NovoCure Limited From 02/15/23

Final data from the PANOVA-3 study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of...

Summary As NovoCure Limited delivers hope in seemingly hopeless situations, Tumor Treating Field is already launched for mesothelioma and glioblastoma multiforme. NovoCure Limited recently generated stellar data for the Phase 3 (LUNAR) trial for non-small cell lung cancer. Amid grea...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

Summary Healthcare is considered a defensive sector and due to the brand name and cheap exposure, Vanguard's ETF prima-facie looks like a promising idea. However, outsized exposure to pharmaceuticals and biotechnology makes VHT a high beta healthcare ETF, undermining its defensive quali...

Novocure ( NASDAQ: NVCR ) said Chief Medical Officer Ely Benaim will step down and leave the company. The company added that the decision was made after a review of Novocure's future needs and that the organizational changes are effective Jan. 17. Piet Hinoul, curren...

Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilit...

Novocure (NASDAQ: NVCR) announced good news earlier this month from a late-stage study evaluating its Tumor-Treating Fields (TTFields) therapy in treating non-small cell lung cancer (NSCLC). Its shares skyrocketed. But just a few days later, the company provided a sneak peek at its ...

H.C. Wainwright reaffirmed the Buy rating on oncology-focused medical equipment maker NovoCure Limited ( NASDAQ: NVCR ) on Thursday despite a loss of ~16% of its value early this week after pre-announcing lower-than-expected Q4 financials. The maker of the Optune brand of cancer treat...

Novocure ( NASDAQ: NVCR ) is down ~15% in Monday afternoon trading after releasing preliminary Q4 2022 figures that came in below estimates. The oncology focused pharma is expecting Q4 net revenue of $128.4 million, below the consensus in $128.69M. As of December 31, 2022, the...

Summary Powered by the robust Phase 3 (LUNAR) trial, NovoCure Limited shares recently rallied over 70% in one trading session. You can expect Tumor Treating Field to be approved for non-small cell lung cancer sometime next year. Later this year, two huge Phase 3 studies are set to r...